



Canadian Fertility and Andrology Society  
Société canadienne de fertilité et d'andrologie

## PRESS RELEASE

**Headline** - The 2025 CFAS Report Shows Shifts in Fertility Care: More genetic testing, fewer multiple pregnancies, and increased use of IVF.

**Québec City, Québec, September 18<sup>th</sup>, 2025** – The Canadian Fertility and Andrology Society (CFAS) unveiled the latest findings from the Canadian Assisted Reproductive Technologies Register (CARTR Plus) during its 71st Annual Meeting, held at the Centre des Congrès de Québec, Quebec City. The report, which includes data from 36 fertility clinics across Canada, offers critical insights into treatment outcomes, patient demographics, and emerging trends in assisted reproductive technologies.

The Canadian Assisted Reproductive Technologies Register (CARTR Plus) Annual Report, presented in collaboration with BORN Ontario (Better Outcomes and Registry Network), highlights several key findings:

- **Live birth rates** - In 2023, a total of 8,870 infants were born in Canada through IVF. Among individuals who underwent at least one embryo transfer within a year, live birth rates ranged from 38% to 50%. These rates vary by age, with success rates declining as age increases.
- **Growing proportion of IVF births** – In Ontario, 3.0% of all live births are conceived via IVF treatment. This has increased from 1.7% since birth outcome data was first collected in 2014.
- **Multiple pregnancy rates** continue to decline to an all-time low of 3.2%, reflecting a national shift towards single-embryo transfer practices resulting in healthier outcomes.
- **Elective oocyte freezing** is steadily increasing, with 2,580 elective oocyte retrievals recorded in 2024 compared to 989 in 2019.
- **Donor oocytes** – In 2023, there were 881 live births from donor oocytes, highlighting the growing role of third-party reproduction in helping families grow.
- **Genetic testing** – Over one third of cycles included preimplantation genetic testing, compared to 21% in 2019. Preimplantation genetic testing is used to help identify embryos with the highest potential for pregnancy and live birth.
- **Provincial funding programs** – Over 5000 patients in Ontario and 2,300 patients in Québec received provincial funding for IVF treatments. These programs cover the cost of one IVF cycle and all associated embryo transfers. We anticipate even greater access to IVF treatments as additional provinces introduce funding programs.

‘This data is essential for improving clinical practice and informing policy,’ said Dr. Neal Mahutte, Co-Chair of the CARTR Plus Steering Committee. ‘It’s exciting to see the impact of provincial support for IVF treatments and we look forward to adding data from British Columbia’s new IVF funding program to future reports,’ added Dr. Jason Hitkari, Co-Chair of the CARTR Plus Steering Committee.

Together, these findings offer a compelling summary of how fertility care in Canada is evolving—becoming safer and increasingly accessible to those building families through assisted reproduction.

The CARTR Plus Annual Report will be available soon through the CFAS.